Why the study?
Direct thrombin inhibitor data in pediatric VAD support have focused on bivalirudin, leaving limited evidence regarding argatroban compared to unfractionated heparin.
Does argatroban reduce bleeding, stroke, and death rates compared to unfractionated heparin in pediatric patients supported by paracorporeal ventricular assist devices?
Does argatroban reduce bleeding, stroke, and death rates compared to unfractionated heparin in pediatric patients supported by paracorporeal ventricular assist devices?
Answers are grounded in this paper and cite their sources.
In pediatric patients requiring paracorporeal VADs, argatroban was not associated with decreased bleeding, stroke, or death rates compared to unfractionated heparin.
Direct thrombin inhibitor (DTI) use has been associated with decreased stroke and death rates in children on ventricular assist devices (VADs). Most information about DTI use for children on VADs has focused on bivalirudin with limited data on argatroban. We hypothesized that, compared to unfractionated heparin (UFH), argatroban would be associated with decreased bleeding, stroke, and death rates in children on VADs. We retrospectively collected data from patients <18 years old on paracorporeal VADs at Children's Wisconsin between January 1, 2010 and July 1, 2021. We divided patients into cohorts based on anticoagulation strategy with heparin or argatroban. Definitions of bleeding and neurologic events were the same as in other published reports on this population. We compared categorical variables with the χ 2 or Fisher's exact test, and continuous variables with the Mann-Whitney U test. Nineteen children were anticoagulated with argatroban, and 16 with heparin. Demographics between groups were not significantly different. Stroke, bleeding, and death rates did not differ between patients treated with UFH versus argatroban. The study population was complex with a high rate of extracorporeal membrane oxygenation (ECMO) use before VAD support, which likely impacted our findings. Our study does not support argatroban as a superior alternative anticoagulant compared to UFH in children requiring VADs.
No takes yet. Share an insight, caveat, or question.
Tuttle et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: